Early identification of high-risk myelosuppression subtypes in DLBCL patients undergoing R-CHOP chemotherapy [PDF]
Frontiers in MedicineBackgroundDespite prophylactic interventions, chemotherapy-related myelosuppression remains an important clinical concern in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP.
Keyi Yang +11 more
doaj +3 more sources
Real-World Management of HMA-Related Myelosuppression During MDS Treatment in the Canadian Landscape [PDF]
Current OncologyHypomethylating agents (HMAs) are the cornerstone in the treatment of higher-risk myelodysplastic syndromes (MDSs), particularly for patients who are not candidates for allogeneic hematopoietic cell transplant (allo-HCT). Despite demonstrated efficacy in
Michelle Geddes +5 more
doaj +2 more sources
Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review [PDF]
Frontiers in OncologyObjectiveWe conducted a retrospective case series of two lung cancer patients treated at Suining Central Hospital (January–March 2025) who developed severe myelosuppression after immune checkpoint inhibitor (ICI) –chemotherapy combination therapy, to ...
Shimin Tang, Na Li, Ji Ma
doaj +2 more sources
Hematopoietic Effects of Angelica gigas Nakai Extract on Cyclophosphamide-Induced Myelosuppression
Plants, 2022 Myelosuppression is a major adverse effect of chemotherapy. With the increasing number of cancer patients worldwide, there is a growing interest in therapeutic approaches that reduce the adverse effects of chemotherapy.
Mincheol Kang +5 more
doaj +2 more sources
[18F]AlF-NOTA-QHY-04 uptake in spleen before anti-tumor therapy may predict degree of myelosuppression for patients with small cell lung cancer [PDF]
Cancer ImagingBackground The aim of this study was to assess the value of C-X-C motif chemokine receptor 4 (CXCR4) targeted positron emission tomography/computed tomography ([18F]AlF-NOTA-QHY-04 PET/CT) imaging in spleen for prediction of degree of myelosuppression in
Siyu Cai +10 more
doaj +2 more sources
A multidimensional investigation of myelosuppression associated with sintilimab: integrating pharmacovigilance signal mining with real-world clinical evidence [PDF]
Frontiers in PharmacologyObjectiveSintilimab, a programmed cell death protein 1 (PD-1) inhibitor, is widely used in cancer immunotherapy, but its hematological toxicity profile in real-world settings remains incompletely understood. This study aims to comprehensively investigate
Shiquan Liu +5 more
doaj +2 more sources
Linezolid-Induced Myelosuppression
Annals of Internal Medicine: Clinical CasesLinezolid is an antibiotic effective against resistant gram-positive bacteria. While side effects are typically mild, myelosuppression can occur, with pancytopenia being a rare but serious condition.
Kristiana Jordan, Kristen D. Kelley
doaj +2 more sources
Myelosuppression with Oxazolidinones: Are There Differences? [PDF]
Antimicrobial Agents and Chemotherapy, 2019 We read with interest Lee & Caffrey’s paper ([1][1]) comparing thrombocytopenia events in association with tedizolid and linezolid from the FDA Adverse Event Reporting System (FAERS), a database of voluntary spontaneous AE reports submitted to the FDA (
Carisa de Anda
exaly +3 more sources
Frontiers in Pharmacology, 2021 The aim of this study was to investigate the correlation between genetic polymorphisms of azathioprine-metabolizing enzymes and adverse reactions of myelosuppression. To this end, a retrospective analysis was performed on 1,419 Chinese patients involving
Zhao-Yang Chen +16 more
doaj +1 more source
Frontiers in Oncology, 2021 Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HPSCs) often results in myelosuppression that adversely affects patient health and quality of life. Currently, chemotherapy-induced myelosuppression is managed with chemotherapy dose
Gary H. Lyman +3 more
doaj +1 more source